Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis

To identify predictors of 10‐year Expanded Disability Status Scale (EDSS) change after treatment initiation in patients with relapse‐onset multiple sclerosis.

[1]  A. Gustavsson,et al.  Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. , 2012, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

[2]  M. Daumer,et al.  Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS , 2011, Neurology.

[3]  C. Pozzilli,et al.  Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  M. Hutchinson,et al.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.

[5]  Xuming He,et al.  A Lack-of-Fit Test for Quantile Regression , 2003 .

[6]  M. Hutchinson,et al.  Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .

[7]  A. Gustavsson,et al.  Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries , 2012, Multiple sclerosis.

[8]  O. Andersen,et al.  Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. , 1995, Brain : a journal of neurology.

[9]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[10]  P. Gustafson,et al.  Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.

[11]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[12]  L. Kappos,et al.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS , 2006, Neurology.

[13]  S. Borg,et al.  Costs and quality of life in multiple sclerosis patients with spasticity , 2014, Acta neurologica Scandinavica.

[14]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[15]  B. Dr. C. Hirst MB,et al.  Contribution of relapses to disability in multiple sclerosis , 2008, Journal of Neurology.

[16]  P. Gustafson,et al.  Practice of Epidemiology Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort , 2014 .

[17]  G. Comi,et al.  Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[18]  B. Haslinger,et al.  Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta , 2013, Neuropsychiatric disease and treatment.

[19]  L. Kappos,et al.  MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.

[20]  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. , 1998, Lancet.

[21]  Deborah M. Miller,et al.  Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. , 2010, Archives of neurology.

[22]  J. Wolinsky,et al.  A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients , 2006, Multiple sclerosis.

[23]  J. Lechner-Scott,et al.  Predictors of disability worsening in clinically isolated syndrome , 2015, Annals of clinical and translational neurology.

[24]  M. Trojano,et al.  New natural history of interferon-beta-treated relapsing multiple sclerosis. , 2007, Annals of neurology.

[25]  J. Lechner-Scott,et al.  Predictors and dynamics of postpartum relapses in women with multiple sclerosis , 2014, Multiple sclerosis.

[26]  Pierre Grammond,et al.  Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.

[27]  M. Trojano,et al.  New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .

[28]  L. Kappos,et al.  Comparative efficacy of switching to natalizumab in active multiple sclerosis , 2015, Annals of clinical and translational neurology.

[29]  R. Rudick,et al.  Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study , 2010, Multiple sclerosis.

[30]  M. D'hooghe,et al.  Pregnancy and multiple sclerosis: the influence on long term disability , 1994, Clinical Neurology and Neurosurgery.

[31]  E. Granieri,et al.  The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis , 2006, Multiple sclerosis.

[32]  B. Cree,et al.  Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? , 2014, JAMA neurology.

[33]  Richard A. C. Hughes,et al.  PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.

[34]  L. Roccatagliata,et al.  Surrogate endpoints for EDSS worsening in multiple sclerosis , 2010, Neurology.

[35]  L. Kappos,et al.  Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15 , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  M. Sylvestre,et al.  Does pregnancy alter the long-term course of multiple sclerosis? , 2014, Annals of epidemiology.

[37]  Dana Horakova,et al.  Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.

[38]  J. Byrnes,et al.  Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  M. Stromillo,et al.  Refining response to treatment as defined by the Modified Rio Score , 2013, Multiple sclerosis.

[40]  J. Lechner-Scott,et al.  Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. , 2015, JAMA neurology.

[41]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[42]  R. Rudick,et al.  Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.

[43]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[44]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.

[45]  L. Kappos,et al.  Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study , 2011, Therapeutic advances in neurological disorders.

[46]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[47]  R. Rudick,et al.  Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients , 2005, Multiple sclerosis.

[48]  B. Taylor,et al.  The economic impact of multiple sclerosis in Australia in 2010 , 2013, Multiple sclerosis.

[49]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[50]  G. Nagels,et al.  Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis , 2012, Journal of Neurology.

[51]  F. Lublin,et al.  Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.